PURPOSE: To review treatment strategies in neovascular age-related macular degeneration (ARMD). METHODS: Medline and Embase search. RESULTS: Age-related macular degeneration (ARMD) is the commonest cause of blindness in the developed world in individuals over 50 years of age. ARMD may lead to loss of vision by atrophy of the retinal pigment epithelium or by the development of choroidal neovascular membranes (CNVM) under the macula, which leak serous fluid and blood and ultimately cause a blinding disciform scar. Treatment options currently being investigated fall into three main approaches: elimination of the CNVM from the subfoveal area (by laser or surgery), modification of the CNVM (by laser, radiotherapy or chemotherapeutic agents) or lastly prevention of the formation of CNVM (by laser prophylaxis, diet or gene targeting). Whilst almost no therapy restores normal visual acuity, any significant visual improvement over the natural history may be regarded as beneficial. CONCLUSIONS: Both the current and immediate future potential therapies for choroidal neovascularisation in ARMD require considerable advances to be made before they will make any impact on blindness caused by ARMD. Of the current treatments none are curative and the treatment benefits are small. There is an urgent need for new therapies.
PURPOSE: To review treatment strategies in neovascular age-related macular degeneration (ARMD). METHODS: Medline and Embase search. RESULTS: Age-related macular degeneration (ARMD) is the commonest cause of blindness in the developed world in individuals over 50 years of age. ARMD may lead to loss of vision by atrophy of the retinal pigment epithelium or by the development of choroidal neovascular membranes (CNVM) under the macula, which leak serous fluid and blood and ultimately cause a blinding disciform scar. Treatment options currently being investigated fall into three main approaches: elimination of the CNVM from the subfoveal area (by laser or surgery), modification of the CNVM (by laser, radiotherapy or chemotherapeutic agents) or lastly prevention of the formation of CNVM (by laser prophylaxis, diet or gene targeting). Whilst almost no therapy restores normal visual acuity, any significant visual improvement over the natural history may be regarded as beneficial. CONCLUSIONS: Both the current and immediate future potential therapies for choroidal neovascularisation in ARMD require considerable advances to be made before they will make any impact on blindness caused by ARMD. Of the current treatments none are curative and the treatment benefits are small. There is an urgent need for new therapies.
Authors: Motasem Al-Latayfeh; Paolo S Silva; Jennifer K Sun; Lloyd Paul Aiello Journal: Cold Spring Harb Perspect Med Date: 2012-06 Impact factor: 6.915
Authors: Brian J Raisler; Kenneth I Berns; Maria B Grant; Denis Beliaev; William W Hauswirth Journal: Proc Natl Acad Sci U S A Date: 2002-06-18 Impact factor: 11.205